Skip to main content
NNVC
NYSE Life Sciences

NanoViricides Q1 Loss Widens to $5.7M; Going-Concern Doubt and ATM Sales Begin

Arie Shkolnikov · Analysis by Wiseek AI
Sentiment info
Negative
Importance info
8
Price
$1.23
Mkt Cap
$31.651M
52W Low
$0.85
52W High
$1.93
52W Position info
45% above low
Off High info
36% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

NNVC sits 45% above its 52-week low of $0.85 on light trading volume (0.2× avg).

Summary

NanoViricides posted a $5.7 million quarterly loss as clinical trial spending ramped up, disclosed substantial doubt about its ability to continue as a going concern, and began small ATM share sales in November.


Key Events · Earnings and Guidance · NNVC

  • Quarterly Loss Widens Sharply

    Net loss was $5,742,936, or $0.23 per share, versus $1,785,058, or $0.10 per share, a year earlier.

  • Trial Costs Drive R&D Surge

    Research and development expense rose to $4,697,186 from $993,066, driven by the Mpox and Ebola Phase II clinical trials in the DRC.

  • Going-Concern Warning Disclosed

    Cash of $2,575,227 plus the $3 million line of credit will not fund planned operations for at least 12 months; substantial doubt exists about continuing as a going concern.

  • ATM Sales Have Begun

    From November 11 to November 13, 2026 the company sold 3,051 shares at an average of $1.40 for about $4,000 in net proceeds under its D. Boral at-the-market program.


Analysis · NNVC · Life Sciences

The loss more than tripled year over year as the Mpox and Ebola Phase II trials in the DRC moved into execution, and management now says cash plus the $3 million line of credit will not fund operations for 12 months. With only $2.6 million of cash against $3.2 million of current liabilities, the company depends on raising more money. It has already started selling into its at-the-market program, though the first three days raised only about $4,000, so the funding gap is real and near-term.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NNVC was trading at $1.23 on NYSE in the Life Sciences sector, with a market capitalization of approximately $31.7M. The 52-week trading range was $0.85 to $1.93. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NNVC - Latest Insights